RVNC - Revance Therapeutics GAAP EPS of -$0.88 beats by $0.03 revenue of $28.37M beats by $0.6M

• Revance Therapeutics press release ( NASDAQ: RVNC ): Q2 GAAP EPS of -$0.88 beats by $0.03 .
• Revenue of $28.37M (+50.9% Y/Y) beats by $0.6M .
• Shares -10.3% .
• 2022 Financial Outlook
• Revance expects 2022 GAAP operating expenses to be $375 million to $400 million and non-GAAP operating expenses, which exclude costs of revenue, depreciation, amortization and stock-based compensation to be $260 million to $280 million. Revance expects 2022 non-GAAP research and development expense to be $100 million to $110 million. With the current cash, cash equivalents and short-term investments of $233.8 million, management projects that the company is funded into 2024, with an additional $100 million in notes available under the company’s note purchase agreement, subject to the FDA approval of DaxibotulinumtoxinA for Injection for glabellar lines.

For further details see: